Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to develop a robust pipeline of novel medicines in immunology, inflammation, and neurology, announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 8:50 AM ET.
This page requires Javascript.
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to develop a robust pipeline of novel medicines in immunology, inflammation, and neurology, announced today that its President and Chief Executive Officer, Marcelo Bigal, M.D., Ph.D., will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023 at 8:50 AM ET.
This page requires Javascript.
Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Hi there, I am Amanda and I work as an editor at impactinvesting.ai; if you are interested in my services, please reach me at amanda.impactinvesting.ai
